Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.
TriSalus Life Sciences Inc. (TLSI) is a biotechnology innovator advancing targeted drug delivery systems and immune-oncology therapies for liver and pancreatic cancers. This page provides authorized updates on clinical developments, financial announcements, and strategic initiatives directly from the company.
Investors and researchers will discover timely updates on TriSalus' Pressure Enabled Drug Delivery (PEDD) technology platform, therapeutic candidate nelitolimod, and TriNav® device advancements. Our curated news collection ensures access to verified press releases, regulatory milestones, and partnership announcements – critical for evaluating the company's progress in oncology innovation.
Content spans clinical trial results, peer-reviewed research publications, executive leadership updates, and manufacturing developments. All materials maintain strict compliance with financial disclosure standards while emphasizing TriSalus' mission to improve treatment outcomes through precision medicine.
Bookmark this page for efficient tracking of TLSI's advancements in merging advanced drug delivery with immune response modulation – a dual approach reshaping oncology care paradigms.
TriSalus Life Sciences (Nasdaq: TLSI) has scheduled its third quarter 2024 financial results conference call for Thursday, November 14, 2024, at 9:00 a.m. ET. The company, which focuses on improving outcomes for liver and pancreatic cancer patients through advanced delivery technology and immunotherapy, will discuss Q3 2024 results and provide a business update. The financial results press release will be issued before the call. The event will be accessible via webcast on the company's investor relations website, with a replay available afterward. Interested parties can register online to receive dial-in details.
TriSalus Life Sciences (Nasdaq: TLSI), an oncology company focused on improving outcomes for liver and pancreatic cancer patients, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. Mary Szela, CEO and President of TriSalus, will engage in a fireside chat on Thursday, October 17, 2024, at 12:30 p.m. EDT / 11:30 a.m. CDT.
TriSalus specializes in advanced delivery technology and a novel immunotherapy called nelitolimod. The company aims to enhance treatment outcomes for patients with liver and pancreatic cancer. Interested parties can register for the event through the provided link and find more information about TriSalus and its innovative technologies on the company's website.
TriSalus Life Sciences (Nasdaq: TLSI) has announced the appointment of Dr. Riad Salem to its Scientific Advisory Board. Dr. Salem, the Chief of Interventional Radiology and a Professor at a Chicago institution, brings expertise in radiological research and innovative liver cancer treatments. His addition is expected to support TriSalus's mission in advancing its Pressure Enabled Drug Delivery™ (PEDD™) technology and nelitolimod, a TLR9 agonist.
CEO Mary Szela highlighted Dr. Salem's role in the LEGACY study, which demonstrated significant improvements in response rates and survival using y90 treatment. Dr. Salem will play a important role in the company's DELIVER program, aimed at providing data support for PEDD and nelitolimod in challenging patient populations with liver and pancreatic cancer.
TriSalus Life Sciences (Nasdaq: TLSI) announced the publication of research in the Journal of Vascular and Interventional Radiology demonstrating improved delivery of glass microspheres to liver tumors using their Pressure Enabled Drug Delivery (PEDD) method via the TriNav Infusion System. The study, conducted on transgenic pigs with induced liver tumors, showed:
- 117% increase in tumor penetration with lobar infusions (p=0.004)
- 39% increase in tumor penetration with selective infusions (p=0.032)
- Lobar PEDD delivery was statistically equivalent to conventional selective delivery (p=0.497)
The research suggests that the PEDD method could potentially improve the efficacy and safety of liver cancer treatments by increasing the concentration of therapeutics in tumors compared to adjacent liver tissue.
TriSalus Life Sciences (TLSI) reported strong Q2 2024 results, with revenues of $7.4 million, up 60% year-over-year. The company's gross margin improved to 88% in Q2 2024. TriSalus plans to launch the 'DELIVER' Program in Q3 2024, aiming to expand the addressable market for its TriNav® Infusion System. The company expects to report data from phase 1 trials of nelitolimod in Q4 2024. TriSalus secured up to $50 million in debt financing from OrbiMed to support growth initiatives. The company completed a warrant exchange offer to simplify its capital structure. With current cash and potential additional funding, TriSalus expects to have sufficient runway through the end of 2025.
TriSalus Life Sciences (Nasdaq: TLSI), an oncology company focusing on novel delivery technology integrated with immunotherapy for liver and pancreatic tumors, has announced a conference call and webcast scheduled for August 15, 2024, at 9:00 a.m. ET. The event will discuss financial results for the second quarter ended June 30, 2024, and provide a business update.
A press release detailing the Q2 results will be issued prior to the call. The webcast will be available on TriSalus' investor relations website, with a replay accessible for approximately 90 days after the event. Participants joining by phone must register using an online form to receive dial-in details and a personal pin.
TriSalus Life Sciences (Nasdaq: TLSI) has successfully completed its exchange offer and consent solicitation related to its warrants. The company issued 2,110,366 shares of common stock in exchange for the tendered warrants. This follows the company's Warrant Amendment with Continental Stock Transfer & Trust Company on June 26, 2024, which affects only publicly-traded warrants. Additionally, the SEC declared effective TriSalus' Registration Statement on Form S-4 on June 25, 2024. The company engaged Oppenheimer & Co. Inc. as Dealer Manager and Solicitation Agent, Morrow Sodali as Information Agent, and Continental Stock Transfer & Trust Company as Exchange Agent.
TriSalus Life Sciences (Nasdaq: TLSI) announced the completion of its exchange offer and consent solicitation for warrants. The offer expired on June 25, 2024, allowing holders to exchange warrants for common stock. Approximately 78.89% of public warrants were tendered, but the company did not secure agreements for private placement or working capital warrants. The company will accept all validly tendered warrants for exchange by July 1, 2024. The warrant amendment was approved for public warrants, but not for private placement or working capital warrants. Oppenheimer & Co. served as the dealer manager and solicitation agent.
TriSalus Life Sciences (NASDAQ: TLSI) presented clinical data from its Phase 1b PERIO-02 trial at the ASCO 2024 Annual Meeting. The trial studies the hepatic arterial infusion (HAI) of nelitolimod using TriSalus's proprietary Pressure Enabled Drug Delivery (PEDD) technology in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The 4 mg dose showed promising results with all three patients achieving disease control, including one complete response, one partial response, and one stable disease. Follow-up is ongoing to determine the next steps. The PEDD method aims to improve drug delivery within tumor microenvironments, potentially enhancing treatment efficacy. Median progression-free survival for the 4 mg dose was over 120 days. The study also noted significant immune responses, including increased CD4 and CD8 T cells in liver tumors.
TriSalus Life Sciences (NASDAQ: TLSI), an oncology company, announced an exchange offer and consent solicitation for its various warrants. The initiative aims to simplify the capital structure and reduce the dilutive impact of these warrants. Holders of the Public Warrants, Private Placement Warrants, and Working Capital Warrants are offered to exchange their warrants for 0.30 shares of common stock per warrant. If adopted, the Warrant Amendment will require outstanding warrants to be exchanged at 0.27 shares per warrant. The offer involves up to 4,264,532 shares of common stock and seeks consents from warrant holders to amend the warrant agreements. The offer expires on June 25, 2024, and is managed by Oppenheimer & Co. Inc.
